Remove Packaging Remove Vaccination Remove Vaccine
article thumbnail

How did pharma develop a vaccine so quickly?

World of DTC Marketing

OBSERVATION: Biologics can take a long time to develop but COVID vaccines have been in development for almost 50 years and novel approaches were used to develop these vaccines. Vaccines typically take 10 to 15 years to develop, test and release to the public. The coronavirus vaccines, however, took less than a year.

Vaccine 307
article thumbnail

Prefilled syringes and vaccines: Optimising parenteral packaging for the next pandemic

Pharmaceutical Technology

When it comes to vaccines and other high-value biologics, it is essential that effective formulations go hand in hand with safe delivery. An example is the ability of a patient suffering from venous thrombosis to perform their own injections of heparin – an anticoagulant often packaged in a prefilled syringe.

Packaging 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biovac and IVI enter deal to develop oral cholera vaccine

Pharmaceutical Technology

South African bio-pharmaceutical firm Biovac and the International Vaccine Institute (IVI) in South Korea have signed a licencing and technology transfer agreement for developing and manufacturing an oral cholera vaccine (OCV).

Vaccine 147
article thumbnail

Biovac receives IFC loan for vaccine manufacturing in Africa

Pharmaceutical Technology

Biovac has received an investment and advisory package from the IFC to support vaccine manufacturing and pandemic preparedness in Africa.

article thumbnail

7 Problems with Using Borosilicate Glass to Package Drugs

Pharma Mirror

By Christopher Weikart, Chief Scientist, SiO2 Materials Science Even though drugs are meant to save lives, the primary packaging used for delivering drug therapies and vaccines may actually be putting us in danger. The post 7 Problems with Using Borosilicate Glass to Package Drugs appeared first on Pharma Mirror Magazine.

Packaging 130
article thumbnail

CanSinoBIO developed a highly effective COVID vaccine with an inhalant version

pharmaphorum

MBA, managing director at CanSino Biologics Europe, tells us about Convidecia, a single dose SARS-CoV-2 vaccine offered as an injectable and inhalant that allows ease of storage, an alternative option for individuals with needle phobias, and robust elongated CD4 and CD8 cellular response. Morgon, PharmD, LL.M, How it works. Regarding the BA.4

Vaccine 138
article thumbnail

Merck and Orna partner for RNA technology-based vaccines and therapies

Pharmaceutical Technology

These programmes will include therapies and vaccines in infectious disease and oncology areas. These molecules synthesised newly are packaged densely into custom lipid nanoparticles (LNPs), which Orna has made to act on the body’s crucial tissues. We look forward to working with the talented scientific and technical teams at Orna.”.

RNA 147